Joining FORCEs Newsletter

Joining FORCES is the FORCE newsletter with news, views and supportive information for individuals concerned about hereditary breast and ovarian cancer.

What's New @ FORCE

FORCE to Testify to FDA in Favor of New PARP Inhibitor Approval

On June 25, the Oncologic Drugs Advisory Committee (ODAC) of the FDA will discuss AstraZeneca Pharmaceuticals — new drug application for olaparib (a PARP inhibitor) capsules as maintenance treatment of patients with platinumsensitive relapsed ovarian cancer who have completed chemotherapy. The public meeting will take place at the FDA offices outside of Washington, D.C. PARP inhibitors were developed specifically for the treatment of cancers associated with a BRCA genetic mutation.

FORCE has been a strong proponent of PARP inhibitor research, and we will present oral commentary supporting approval of this application. We are hopeful that olaparib will be approved as a new agent for women fighting hereditary ovarian cancer.


We welcome your feedback. Please send your comments to Sue Friedman or fill out our Newsletter Feedback Form.

New to FORCE? Find the information and support you need.

Recognize a Loved One

Wherever you are in the process of determining your cancer risk or risk management options, there is a good chance that other people are going through the same thing and are available to offer support.

Understanding HBOC and BRCA

The Understanding HBOC & BRCA section of this website has a comprehensive collection of information on a variety of topics, and includes links to further in-depth articles, books and websites.

FORCE:Facing Our Risk of Cancer Empowered